Introduction: Many places have increased the number of years for medical insurance payment, or need to pay for 15 more years; heat stroke death cases have occurred in many places; Simcere Pharmaceuticals CDK4/6 inhibitors have been approved for marketing ... Bio-exploration is with you Pay attention to "drug" news and explore the value of biotechnology!
01 Many places have increased the medical insurance payment period
or need to pay for 15 more years
Recently, Shandong, Guangdong and other provinces have introduced new medical insurance policies, which will increase the minimum payment period for medical insurance to 30 years for male employees and 25 years for female employees in the next few years. Years, insured persons must reach the above payment years before they can enjoy medical insurance retirement benefits.
The medical insurance payment period in Shandong Province is 30 years for male employees and 25 years for female employees. For coordinated areas that have not reached the prescribed years, the transition will be in place before the end of 2025; Guangdong Province will gradually unify the medical insurance payment period for employees across the province, and the cumulative payment period will be 1 in 2030 On the first day of the month, the service life is 30 years for male employees and 25 years for female employees.
According to the provisions of the Social Security Law, individuals who participate in the employee basic medical insurance, and when they reach the statutory retirement age and their cumulative contributions reach the number of years specified by the state, they will no longer pay basic medical insurance premiums after retirement and enjoy basic medical insurance benefits in accordance with national regulations; If the age limit prescribed by the state is not reached, premiums can be paid until the age limit prescribed by the state.
02 Death cases from heat stroke have occurred in many places
Recently, many hospitals have been sending heatstroke patients to hospital, and many people have been diagnosed with heat stroke and have died. In addition, people have also been diagnosed in Nanjing and Sichuan.
html On July 8, a 49-year-old male patient at Lishui Central Hospital in Zhejiang Province died in the early morning after 31 hours of rescue. The hospital has received three patients with heat stroke in the past week. A 70-year-old woman did not pay attention to heatstroke prevention at home. She developed high fever and confusion while taking a nap. When she was sent to the hospital, her body temperature reached 42.5°C and she suffered multiple organ failure. She is still being rescued.On July 10, West China Hospital of Sichuan University admitted three transferred patients with heat stroke in a row. One of them suffered from respiratory and cardiac arrest when he was transferred to West China Hospital due to severe illness and multiple organ failure. Despite all efforts to rescue him, he unfortunately died in the end.
htmlOn July 12, a 37-year-old decoration worker suffered from dizziness and frequent vomiting after working continuously for 4 hours, and was diagnosed with heat stroke by the Jiangsu Provincial Hospital of Traditional Chinese Medicine. It is understood that this is the first case of heat stroke in Nanjing this year.03 Simcere Pharmaceuticals’ CDK4/6
inhibitor has been approved for marketing. On July 13, the official website of the State Food and Drug Administration announced that the new drug application for trilaciclib for injection, an innovative bone marrow protection drug introduced by Simcere Pharmaceuticals, has been approved. Officially approved. Triracilide is a CDK4/6 inhibitor. The approved indication is: prophylactic use in patients with extensive-stage small cell lung cancer who receive platinum-containing drugs combined with etoposide to reduce the risk of Incidence of chemotherapy-induced myelosuppression.
04 New drug for dry eye disease
achieved primary and secondary endpoints
On July 13, Aldeyra Therapeutics announced that its research reproxalap eye drops achieved the primary and secondary endpoints of the trial in a crossover clinical trial for the treatment of dry eye patients. What was announced this time were the results of a randomized, double-blind and crossover clinical trial with the carrier as the control group. Data analysis showed that after one day of treatment with reproxalap (0.25%), patients had better outcomes in the trial's two primary endpoints, eye redness in dry eye chamber (P=0.0004) and Schirmer's In the test (P=0.0005), they were statistically significantly better than the vehicle control group. The Schirmer test is a method of measuring tear production. A diameter of 10 mm or more on the Schirmer test is considered to be associated with relief of dry eye symptoms. Aldeyra expects to hold a pre-new drug application meeting with the U.S. Food and Drug Administration in the third quarter of 2022 and subsequently submit a new drug application.
05 Huahai Pharmaceutical Net profit in the first half of the year
is expected to increase by 10%-15%
On July 13, Huahai Pharmaceutical announced that the company’s net profit attributable to shareholders of listed companies in the first half of 2022 is expected to be between 565 million yuan and 591 million yuan. Yuan, an increase of about 10% to 15% year-on-year.The main reasons are: 1) With the promotion of nationwide centralized procurement and the lifting of the US FDA ban, the increase in domestic market demand and the recovery of the US market have driven the production of preparations and APIs. On the other hand, the company's lean management has begun to show results. Factors such as steady growth in sales of APIs and intermediate products and a slight increase in selling prices have affected the company's substantial increase in main business profits; 2) As the U.S. dollar exchange rate rose sharply in this period, the company's exchange income increased significantly.
finishing | text selection
typesetting | text selection
End
